Overview

Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, phase I/II, single-center study with dose finding and dose expansion parts. This study hypothesizes that the combination of platinum-based chemotherapy, Oregovomab and Nivolumab will improve intracellular CA 125 antigen processing and elicit a stronger systemic CA 125-specific T cell response and that it will be in a manner that is synergistic, safe and clinical efficacious in patients with relapsed platinum sensitive epithelial ovarian carcinoma (EOC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Cancer Centre, Singapore

Collaborators:

Bristol-Myers Squibb
OncoQuest Inc.
OncoQuest Pharma USA Inc.

Treatments:

Nivolumab
Oregovomab